Farmacia en los sistemas de salud para la atención a pacientes ambulatorios: evolucionando

ALZUETA ISTURIZ N, FONTELA BULNES C, ECHEVERRÍA GORRITI A, GIL SETAS A, ALDAZ HERCE P, GARJÓN PARRA J. Resultados de la implementación de un programa piloto de optimización de antimicrobianos (PROA) en Atención Primaria. An Sist Sanit Navar 2020; 43(3): 373-379. https://doi.org/10.23938/ASSN.0913

GUTIÉRREZ‐VALENCIA M, IZQUIERDO M, BEOBIDE‐TELLERIA I, FERRO-URIGUEN A, ALONSO-RENEDO J, CASAS-HERRERO A et al. Medicine optimization strategy in an acute geriatric unit: The pharmacist in the geriatric team. Geriatr Gerontol Int 2019; 19(6): 530-536. https://doi.org/10.1111/ggi.13659

ALZUETA N, FONTELA C, ECHEVERRÍA A. A strategy for urinary incontinence treatments deprescription. Med Clin (Barc) 2021; 156(9): 465-466. https://doi.org/10.1016/j.medcli.2020.04.044

Proyecto MARC. Elaboración de una lista de medicamentos de alto riesgo para los pacientes crónicos. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2014. https://www.seguridaddelpaciente.es/resources/documentos/2014/Proyecto_MARC_2014.pdf.

CLYNE B, FITZGERALD C, QUINLAN A, HARDY C, GALVIN R, FAHEY T et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. J Am Geriatr Soc 2016; 64(6): 1210-1222. https://doi.org/10.1111/jgs.14133

OLRY DE LABRY LIMA A, SALAMANCA-FERNÁNDEZ E, ALEGRE DEL REY EJ, MATAS HOCES A, GONZÁLEZ VERA MÁ, BERMÚDEZ TAMAYO C. Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews. An Sist Sanit Navar 2021; 44(2): 261-273. https://doi.org/10.23938/ASSN.0965

MARQUINA-MÁRQUEZ A, OLRY-DE-LABRY-LIMA A, BERMÚDEZ-TAMAYO C, FERRER LÓPEZ I, MARCOS-MARCOS J. Identifying barriers and enablers for benzodiazepine (de)prescription: a qualitative study with patients and healthcare professionals. An Sist Sanit Navar 2022; 45(2): e1005. https://doi.org/10.23938/ASSN.1005

ARANGUREN I, ELIZONDO G, AZPARREN A. Consideraciones de seguridad de los AINE. Bol Inf Farmacoter Navar 2016; 24(2): 1-12. http://www.navarra.es/NR/rdonlyres/CFA8CDF9-77DA-47BD-8B0B-7C961EFF550B/358992/Bit_v24n2.pdf.

AZPARREN A, GARCÍA I. Estrategias para la deprescripción de benzodiazepinas. Bol Inf Farmacoter Navar 2014; 22(2): 1-13. https://www.navarra.es/NR/rdonlyres/AB30A9A5-9907-4D68-A17A-C4AB0DC524D5/293282/Bit_v22n2.pdf.

ALZUETA N, CELAYA M, ACIN M, ECHEVERRÍA A, FONTELA BULNES C, SANZ L et al. 5PSQ-097 Triple whammy interaction: improving patients’ safety. Eur J Hosp Pharm. 2019; 26(Suppl 1): A246. https://doi.org/10.1136/ejhpharm-2019-eahpconf.530

Portal de la Salud Navarra. Uso y manejo de mis medicamentos. http://www.navarra.es/home_es/Temas/Portal+de+la+Salud/Ciudadania/Mi+enfermedad/Uso+y+manejo+de+mis+medicamentos/

RODRÍGUEZ ESQUÍROZ A, SANZ ÁLVAREZ L, MARÍN MARÍN M, GARCÍA GONZÁLEZ P, ALDAVE COBOS P, GARJÓN PARRA J. Análisis de las interacciones de nirmatrelvir/ritonavir en pacientes ambulatorios en atención primaria. An Sist Sanit Navar 2023; 46(3): e1056.

MONFORTE GASQUE MP, LÁZARO GALLARDO EM, LÁZARO CASTELLANO AM, QUEROL HERNÁNDEZ AC, MAROTO GARCÍA E, BORRÁS MARTÍ F. Evaluación del dolor en pacientes con patologías reumáticas en tratamiento con terapias biológicas. An Sist Sanit Navar 2022; 45(3): e1020. https://doi.org/10.23938/ASSN.1020

CASO-GONZÁLEZ A, NÚÑEZ-RODRÍGUEZ J, GONZÁLEZ-PÉREZ Y, LERALTA-GONZÁLEZ C, SANZ-ALONSO V, OBALDIA-ALAÑA C. Effectiveness on adherence to biological drugs and experience of a pharmaceutical intervention based on CMO model in patients with rheumatic disease (AdhER-2 study). An Sist Sanit Navar 2022; 45(2): e1004. https://doi.org/10.23938/ASSN.1004

MARÍN-GORRICHO R, LOZANO C, TORRES C, et al. Impacto de la atención farmacéutica en pacientes polimedicados ingresados en un servicio de Geriatría. An Sist Sanit Navar 2022; 45(1): e0990. https://doi.org/10.23938/ASSN.0990

MORILLO-VERDUGO R, CALLEJA-HERNÁNDEZ MÁ, ROBUSTILLO-CORTÉS M DE LA, POVEDA-ANDRÉS JL. Una nueva definición y reenfoque de la atención farmacéutica: el Documento de Barbate. Farm Hosp 2020; 44(4): 158-162. https://doi.org/10.7399/fh.11389

REEVE J, MADEN M, HILL R, TURK A, MAHTANI K, WONG G et al. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. Health Technol Assess 2022; 26(32): 1-148. https://doi.org/10.3310/AAFO2475

TARRANT C, LEWIS R, ARMSTRONG N. Polypharmacy and continuity of care: medicines optimisation in the era of multidisciplinary teams. BMJ Qual Saf 2023; 32(3): 121-124. https://doi.org/10.1136/bmjqs-2022-015082

CROKE A, CARDWELL K, CLYNE B, MORIARTY F, MCCULLAGH L, SMITH SM. The effectiveness and cost of integrating pharmacists within general practice to optimize prescribing and health outcomes in primary care patients with polypharmacy: a systematic review. BMC Prim Care 2023; 24(1): 41. https://doi.org/10.1186/s12875-022-01952-z

HASAN IBRAHIM AS, BARRY HE, HUGHES CM. A systematic review of general practice-based pharmacists’ services to optimize medicines management in older people with multimorbidity and polypharmacy. Fam Pract 2021; 38(4): 509-523. https://doi.org/10.1093/fampra/cmaa146

MANN C , ANDERSON C, AVERY AJ, WARING J, BOYD M. Clinical Pharmacists In General Practice : Pilot Scheme : Independent Evaluation Report: Full Report. NHS England. 2018. https://doi.org/10.17639/re5w-wp51

ANDERSON C, ZHAN K, BOYD M, MANN C. The role of pharmacists in general practice: A realist review. Res Social Adm Pharm 2019; 15(4): 338-345. https://doi.org/10.1016/j.sapharm.2018.06.001

HURLEY E, GLEESON LL, BYRNE S, WALSH E, FOLEY T, DALTON K. General practitioners’ views of pharmacist services in general practice: a qualitative evidence synthesis. Fam Pract 2022; 39(4): 735-746. https://doi.org/10.1093/fampra/cmab114